PMC:7696151 / 34047-34349
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 972 | 65-71 | Chemical | denotes | sodium | MESH:D012964 |
| 973 | 82-92 | Chemical | denotes | mexiletine | MESH:D008801 |
| 974 | 96-105 | Chemical | denotes | lidocaine | MESH:D008012 |
| 975 | 244-251 | Chemical | denotes | HCQ/AZM |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T45 | 274-296 | Phenotype | denotes | prolonged QT intervals | http://purl.obolibrary.org/obo/HP_0001657 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T227 | 0-302 | Sentence | denotes | It has also been suggested that the use of drugs that block late sodium channels (mexiletine or lidocaine) and close attention to serum electrolytes, in addition to the evaluation of heart rate and QT intervals, may allow the administration of HCQ/AZM even in subjects with prolonged QT intervals [54]. |